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ABSTRACT 
 
In biomedical research and translational medicine, the ancient war between 
exclusivity (private control over information) and access to information is 
proposing again on a new battlefield: research biobanks. The latter are becoming 
increasingly important (one of the ten ideas changing the world, according to 
Time magazine) since they allow to collect, store and distribute in a secure and 
professional way a critical mass of human biological samples for research 
purposes. Tissues and related data are fundamental for the development of the 
biomedical research and the emerging field of translational medicine: they 
represent the “raw material” for every kind of biomedical study. For this reason, 
it is crucial to understand the boundaries of Intellectual Property (IP) in this 
prickly context. In fact, both data sharing and collaborative research have 
become an imperative in contemporary open science, whose development 
depends inextricably on: the opportunities to access and use data, the possibility 
of sharing practices between communities, the cross-checking of information and 
results and, chiefly, interactions with experts in different fields of knowledge. 
Data sharing allows both to spread the costs of analytical results that researchers 
cannot achieve working individually and, if properly managed, to avoid the 
duplication of research. These advantages are crucial: access to a common pool 
of pre-competitive data and the possibility to endorse follow-on research projects 
are fundamental for the progress of biomedicine. This is why the "open 
movement" is also spreading in the biobank's field. 
After an overview of the complex interactions among the different stakeholders 
involved in the process of information and data production, as well as of the 
main obstacles to the promotion of data sharing (i.e., the appropriability of 
biological samples and information, the privacy of participants, the lack of 
interoperability), we will firstly clarify some blurring in language, in particular 
concerning concepts often mixed up, such as “open source” and “open access”. 
The aim is to understand whether and to what extent we can apply these 
concepts to the biomedical field. Afterwards, adopting a comparative perspective, 
we will analyze the main features of the open models – in particular, the Open 
Research Data model – which have been proposed in literature for the 
promotion of data sharing in the field of research biobanks. 
After such an analysis, we will suggest some recommendations in order to 
rebalance the clash between exclusivity - the paradigm characterizing the 
evolution of intellectual property over the last three centuries -  and the actual 
needs for access to knowledge. We argue that the key factor in this balance may 
come from the right interaction between IP, social norms and contracts. In 
particular, we need to combine the incentives and the reward mechanisms 
characterizing scientific communities with data sharing imperative. 
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Intellectual Property, Open Science and 
Research Biobanks 
 
Roberto Caso and Rossana Ducato1 
 
 
 
1. Introduction 
 
 In the last thirty years we have witnessed an overgrowth of 
Intellectual Property Rights (IPRs) almost in every field of our daily 
life2. According to the traditional view, the protection of IP and the 
control of information are key to the strategy of many companies 
and both have been justified with well-known economic and 
utilitarian arguments3: patent, copyright, trademark and other forms 
of exclusive rights offer incentives to undertake risky projects, 
                                                          
1 Roberto Caso is author of paragraphs 1, 2, and 4; Rossana Ducato is author of 
paragraphs 3, 4.1, 5, 6, and 7; while the concluding remarks are the fruit of a joint 
reflection of the two authors. 
 
 
2According to Robert Merges, IP law is like Shanghai or other megacities of the 
developing world, where new constructions and buildings proliferate everywhere 
without taking into account the urban planning of the old city. The author 
concludes his metaphor asserting that: “It’s an exciting time, to be sure; but a 
confusing time too”. Merges, 2011. 
3 See also Ladas, 1929; Plant, 1934; Nordhaus, 1969; Mazzoleni and Nelson, 1998; 
Menell, 1999; Landes and Posner, 2003. 
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represent the main source of appropriating returns, can lead to a 
“more equitable distribution of profits across all stages of R&D”4 
and are the better antidote for corporate secrecy.  
At the same time, the public domain has suffered a slow but 
constant erosion. Legislators have supported this trend towards 
privatization, progressively attributing to multiple owners a set of 
rights to exclude others5. Governments have been creating this 
dangerous dominance through some interventions in patent law and 
copyright law, such as the Bayh-Dole Act6, the Digital Millennium 
Copyright Act7, the Sonny Bono Copyright Extension Act8 in the 
U.S. or Directives 91/250/EEC (replaced by Directive 
2009/24/EC)9, 96/9/EC10, 98/44/EC11, 2001/29/EC12 or 
                                                          
4 Heller and Eisenberg, 1998, p. 698. 
5 See Heller and Eisenberg, 1998; Lessig, 2004; Boyle, 2008. 
6 Bayh-Dole Act is a watershed from the past patent regimes. First of all, it 
introduces the possibility of patenting results of publicly funded research. 
Secondly, it allows university and public laboratories to sell exclusive licenses to 
private companies or to create partnership with them in order to economically 
exploit the research results and to translate their basic research into marketable 
products. See Rai and Eisenberg, 2003; Coriat and Weinstein, 2011. 
7 Digital Millennium Copyright Act, 17 U.S. Code. This statute has qualified as a 
criminally relevant behavior the circumvention of technological protection 
measures and the distribution of tools to encompass DRM. 
8 Copyright Term Extension Act, 17 U.S. Code, also known as Mickey Mouse 
Protection Act, extended copyright terms in the U.S.A. as following: duration of 
copyright protection is raised from 50 to 70 years after the death of the author 
and it lasts 120 years after creation or 95 years after publication if it is a work of 
corporate authorship. 
9 Council Directive 91/250/EEC of 14 May 1991 on the legal protection of 
computer programs, in Official Journal L 122 of 17 May 1991, replaced by 
Directive 2009/24/EC of the European Parliament and of the Council of 23 
April 2009 on the legal protection of computer programs, in Official Journal L 
111, 05/05/2009, p. 16–22. 
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2004/48/EC13 in the European Union. Such national or regional 
legislation is reflected in a number of international provisions like 
the WTO’s Agreement on Trade Related Aspects of Intellectual 
Property Rights (1994) or the World Intellectual Property 
Organization “Internet” Treaties (WIPO Copyright Treaty and the 
WIPO Performances and Phonograms Treaty), and it has also been 
confirmed by relevant judicial decisions14. This progressive 
                                                                                                                               
10 Directive 96/9/EC of the European Parliament and of the Council of 11 
March 1996 on the legal protection of databases, in Official Journal L 077 of 27 
March 1996. 
11 Directive 98/44/EC of the European Parliament and of the Council of 6 July 
1998 on the legal protection of biotechnological inventions, in Official Journal L 
213 of 30 July1998. 
12 Directive 2001/29/EC of the European Parliament and of the Council on the 
harmonization of certain aspects of copyright and related rights in the 
information society, in Official Journal L 167 of 22 June 2001. The importance of 
IP protection is stressed in whereas 4 and 9. 
13 Directive 2004/48/EC of the European Parliament and of the Council on the 
enforcement of intellectual property rights, in Official Journal L 157 of 30 April 
2004. See whereas 10: “The objective of this Directive is to approximate 
legislative systems so as to ensure a high, equivalent and homogeneous level of 
protection in the internal market”. 
14 Taking as an example the case law of the United States, because its parabola 
serves to illustrate the evolution of the trend towards enclosure, regarding patents 
we can mention Diamond v. Chakrabarty, 447 U.S. 303 (1980), affirming that 
“anything under the sun made by man is patentable”, and introducing the patent 
protection for micro-organism; State Street Bank and Trust Company v. Signature 
Financial Group Inc., 149 F. 3d 1368 (1998), establishing the patentability of 
business methods in the United States; Appeal from the United States District 
Court for the Southern District of New York in Case No. 09-CV-4515 
(Association for Molecular Pathology v. UPO) overruling the revolutionary 
judgment of the NY District court which had invalidated the Myriad patents on 
BRCA gene in virtue of the “product of nature” doctrine. The Court of Appeal 
overruled the decision of the inferior court and confirmed the principle that 
isolated DNA is a distinct chemical entity with different physical characteristics 
from natural DNA, so eligible for patent protection under 35 USC §101. Last 
  4
transformation has been creating the conditions for new 
institutional complementarities between IPR and finance, opening 
de facto to capital the door of the “workshop” of knowledge15. 
A set of interventions in the public and private sector has 
significantly contributed to this “second enclosure movement”, 
shifting the balance of power towards private control and increasing 
the risk of non-use or under-utilization of information16. In other 
words, we have such a wide range of Intellectual Property tools that 
we can no longer manage it.  
In this perspective, many authors talk about the tragedy of 
anticommons. The tragedy of anticommons is a mirror-image of 
Hardin’s tragedy of the commons17. According to the American 
ecologist Hardin, when multiple individuals can use a shared limited 
resource (in the original example it was an open-access pasture) 
without the right to exclude others, they tend to act independently 
and according to their self-interest, exploiting the resource as much 
                                                                                                                               
year, the Supreme Court finally ended such dispute with a "salomonic" and 
controversial decision, stating that the DNA as such cannot be patented, while 
the so called cDNA (complementary DNA) is a patent-eligible subject matter. 
Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 12-398 (2013). 
See, Kesselheim, Cook-Deegan, Winickoff, and Mello, 2013. With regard to 
copyright Eldred v. Ashcroft, 123 S.Ct 769 (2003) is significant, a decision that 
seems to attribute to Congress the possibility of extending the validity of 
copyright without apparently any limit (see Samuelson, 2003; Lessig, 2004; 
Kranich, 2006); more specifically on file sharing, see the famous ruling of A&M 
Records v. Napster, 239 F.3rd 1004 (9th Cir. 2001); MGM Studios Inc. v. Grokster 
Ltd, 545 U.S. 913 (2005). 
15 Coriat and Weinstein, 2011. 
16 Boyle, 2003. 
17 Parisi et al., 2005. 
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as possible. In this way, the common good is prone to be 
overgrazed18; meanwhile, in the tragedy of anticommons the social 
dilemma is the opposite: the common resource risks being 
underused because individuals have a right to exclude others and no 
owner has effectively a privilege of use19.  
The danger of the anticommons tragedy is particularly sharpened in 
the current biomedical research, the development of which depends 
inextricably on the opportunity to access and use data, materials, 
know-how and, consequently, on the possibility of cross-checking 
pre-competitive information and results. 
The scenario described so far gives rise to the risk that rigid and 
centralized control of information based on many and strong IPRs, 
shaped on market considerations, invades the proper domain of the 
scientific community (which is, on the contrary, motivated by the 
logic of flexible and decentralized control, based on customs and 
informal norms), decreasing the possibility of access to scientific 
knowledge. 
To counteract this risk, part of the scientific community is 
promoting the logic of “open intellectual property” to scientific 
knowledge20. In fact, the emersion of initiatives based on contracts 
(licenses) such as the Open Source movement or Creative 
Commons reveals different perspectives with regard to the statutory 
                                                          
18 Hardin, 1968. 
19 Michelman, 1967; Heller, 1998; Heller, 1999. 
20 The "Open approach" to genomic data has been explored by Van Overwalle, 
2014. 
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regime of intellectual property. In the last years the movement of 
“open intellectual property” is more and more active in the 
biomedical field. 
In biomedical research and translational medicine, the ancient war 
between the exclusive right (private control over information) and 
public access to information is struggling on a new battlefield: 
research biobanks. The latter are becoming increasingly important 
(one of the ten ideas changing the world, according to Time 
magazine21) because they collect, store and distribute in a secure and 
professional way a critical mass of human biological samples for 
research purposes. Tissues and related data are fundamental for the 
development of biomedical research and the emerging field of 
translational medicine, because they represent the “raw material” for 
every kind of biomedical study. For this reason it is crucial to 
understand the boundaries of IP in this prickly context. 
After an overview of the complex interactions among the different 
stakeholders involved in the process of the production of 
knowledge, in this paper we will thin out some blurring of language 
concerning concepts often mixed up, such as “open source”, “open 
access”, and their precipitates. Then, the aim is to understand if we 
can use the concepts in the biomedical context, and which are the 
open models proposed in literature specifically for research 
biobanks in order to avoid the tragedy of anticommons. 
                                                          
21  
http://www.time.com/time/specials/packages/completelist/0,29569,1884779,00
.html. 
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2. The rise of the IP war 
 
The dominions of IP had been constantly expanding insomuch as 
undermining the flexibility of the scientific social norms. This is 
evident if we consider, for example, the patent race by academic 
institutions: there is a tension between the patent requirement of 
novelty and the need for the scientist to publish as soon as possible. 
Since the publication of the results frustrates the requirement of 
novelty, the scientists are prohibited from publishing until the 
patent is granted22. In the biomedical field, the formalism of law is 
looked on because it tends to encompass areas that were previously 
managed in a free and independent way by the whole scientific 
community, thus changing informal rules and attitudes.  
This passage is evident if we compare the famous cases of Henrietta 
Lacks and John Moore23. In the first case, scientists who discovered 
the ‘HeLa’ cells - an immortal cell line derived from the biological 
samples of the woman – distributed them to all laboratories around 
the world. In the 50’s those scientists had understood the value of 
that discovery for the progress of science and they decided to share 
their results with other peers and potential competitors24. It was a 
                                                          
22 Streitz and Bennet, 2003; Kinney et al, 2004; Murray and Stern, 2007. 
23  Moore v. Regents of University of California, 51 Cal.3d 120, Supreme Court of 
California, July 9, 1990. 
24 Landecker, 1999; O’Brien, 2001; Lucey et al. 2009; Javitt, 2010; Skloot, 2010. 
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farsighted choice, if we consider that HeLa cells were used in a huge 
amount of research fields: from polio vaccine to gene mapping; 
from the development of the first anti-cancer drugs (such as 
tamoxifen) to space experiments for testing the reactions of the 
human body to the absence of gravity25.  
In the second case, two physicians at UCLA isolated a cell line from 
the spleen of John Moore and they did not have any hesitation: they 
rushed to file a patent application on that invention and the Regents 
of UCLA were designed as assignees of the patent. They 
immediately started to negotiate agreements with two big 
pharmaceutical companies for the commercial exploitation of the 
‘Mo cell’26. 
Is it just a coincidence that within three decades researchers have 
acted so differently? We can try to answer looking at the different 
role that science has taken over the years. Since the beginning of the 
20th Century, science has turned to market, replacing its old form 
                                                          
25 With this statement we do not want to endorse the unethical attitude of 
researchers towards the patient Henrietta Lacks, but only emphasize the easiness 
with which they tended to share certain resources. 
26 Also in this case everything happened behind the patient's back. The Moore 
affair gave rise to a long and famous lawsuit: John Moore, after discovering the 
business built from his cell by Dr. Golde and Dr. Quan, his two physicians at 
UCLA, tried to sue them for breach of fiduciary duty in the doctor-patient 
relationship (both had acted without his informed consent), but above all for the 
recognition of property rights on the patented cell line (he claimed for 
conversion). About this case, see Annas, 1988; Paganelli, 1989; Hipkens, 1992; 
Burrow, 1997; Campbell, 2006. 
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based on the principles of universality and author’s prestige with a 
new form of managerial science characterized by teamwork27.  
This change has been speeded up more recently by legislation which 
has strongly encouraged university and public research centres to 
patent and to transfer their invention to the industry, also through 
the use of exclusive licenses (it is the case of the already mentioned 
Bayh-Dole Act)28. The legislative initiative was welcomed, and has 
yielded significant benefits in the short term. Before 1980, fewer 
than 250 patents per year were issued to US universities. After the 
Bayh-Dole Act, the number of patents increased greatly and 
university's licensing revenues had grown from $221 million in 
1991, to $698 million in 199729. Patents became a source of 
additional funding and income for universities; at the same time, the 
network between university and private sector also allowed 
companies to cut down the costs for research. Just to remain in the 
area of drug discovery, thanks to the basic research done by 
universities and the R&D realized by start-ups in order to bring to 
market academic results, pharmaceutical companies discovered and 
validated new drug targets in a faster and cheaper way.  
This trend toward enclosure, consisting of an elephantiasis in 
patenting, arises parallel to another front: the access to knowledge 
                                                          
27 Johns, 2009. 
28 Heller and Eisenberg, 1998; Mowery, 1998; Caso, 2005; Granieri, 2010; 
Perkmann and West, 2014 
29 Nelson, 2001. Some authors downsized the importance of Bayh-Dole Act in 
the university patent process. See, for example, Mowery et al., 2004; Mowery and 
Sampat, 2005. 
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commons. The prime example is represented by what happened in 
the United States after the Second World War. At the beginning, 
public funds were assigned for the creation of the first databases 
indexing military information, and then also medical and 
educational data30. Through these funds it was possible to create 
new research centres and federal libraries. The wind changed when 
the Reagan administration decided to outsource governmental 
publications, and some federal programs related to libraries, to the 
private sector. Even academic institutions followed this path, 
outsourcing the publication of their journals to private companies. 
Moreover, the mergers in the 70s between publishers created a 
situation of oligopoly, so almost all of the scientific production was 
in the hands of a few big international groups; and consequently the 
price of scientific journals soared. The conditions for triggering a 
vicious cycle had been created: at the end universities invested twice 
for the same thing. In the first instance, they had been investing to 
fund research that would subsequently be given away for free to 
publishers; and they invested a second time to regain that same 
publication, buying for their libraries the subscription to the journal 
at a higher price31. 
This evolution in the ‘80s is crucial because universities and big 
biotech/pharmaceutical companies started to colonize the area of 
pre-competitive research and to make access to knowledge more 
                                                          
30 Such as for example, Dialog System. See Summit, 2002. 
31 Guedon, 2004; Suber, 2004b; Kranich, 2006; Caso, 2009, Reichman, Okediji, 
2012. 
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difficult. Such proliferation of IPRs upstream, while it had a positive 
effect in the short period, has hindered biomedical research in the 
long run32. Covering basic research discoveries, materials and 
reagents with proprietary claims means to inhibit the use of those 
tools that are fundamental not only for downstream research but 
also for basic research itself33. This dangerous stalemate is 
confirmed by the decrease in the number of new patented drugs 
notwithstanding the growing public and private investments in drug 
discovery34. This trend can result from a number of causal factors, 
but as has been pointed out in the literature, the main contributing 
causes are the lack of data sharing and the difficulties in governing 
IPRs35.  
 
 
3. The role of biobanks in life sciences research  
 
Data sharing and collaborative research have become an imperative 
in contemporary science, whose development depends inextricably 
on: the opportunities to access and use data, the possibility of 
sharing practices between communities, the cross-checking of 
information and results and, chiefly, interactions with experts in 
                                                          
32 Rai and Eisenberg, 2003. 
33 This recent trend towards the appropriation of data is posing serious obstacles 
to full and open access to data for scientific purposes. ICSU, 2004. 
34 Booth and Zemmel, 2004; Cuatrecasas, 2006; Weigelt, 2009. 
35 Weigelt, 2009. 
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different fields of knowledge. Data sharing allows both to spread 
the costs of analytical results that researchers cannot achieve 
working individually and, if properly managed, to avoid the 
duplication of research. These advantages are crucial: access to a 
common pool of pre-competitive data and the possibility to endorse 
follow-on research projects are fundamental for the progress of 
biomedicine36. This is why new institutions such as research 
biobanks have gained in importance37.  
Biobanks are powerful tools and organizational structures essential 
for translational medicine and biomedical research, because they are 
treasures of a pool of pre-competitive information and materials 
tempting both public research centres and BigPharma38. On the one 
hand, they are a source of human biological samples stored 
according to high standards of quality and safety. On the other 
hand, a biobank is also an informational ‘mine’; in its databases are 
classified clinical/diagnostic information, sample-derived genetic 
data, donor's personal data, and the type of consent given for the 
research. Such data have a surplus value for translational and 
                                                          
36 The point is analyzed by Tomasson, 2009; see also Conley, Doerr, and 
Vorhaus, 2010 (focusing the data sharing issue in the context of the "Personal 
Genome Project"); Kaye, 2012 (here the author explores some governance 
solutions for the privacy protection of the research participants). 
37 For a broader overview of the phenomenon of biobanks see Macilotti, 2012. 
38 Translational medicine is based on pre-clinical bio-molecular analysis of a 
critical mass of human biological samples in order to obtain results immediately 
usable in the clinical context. This allows the identification of biomarkers, i.e. 
those molecules that can predict the risk of cancer, the presence of a neoplasia 
and the possibility of identifying the most appropriate and effective drug or 
treatment for a particular patient. See FitzGerald, 2005. 
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biomedical research because they are constantly updated with 
donor's follow-up data: it is possible to follow the clinical history, 
the disease progression, the response to different therapies, etc. In 
some cases, research biobanks have also created additional 
resources such as archives of graphical elaborations of protein 
structure (in 2-D or 3-D). 
Thanks to technological and scientific progress, what until a few 
decades ago had been considered a worthless hospital waste (a res 
derelictae), nowadays has become an asset in a legal and economic 
sense. Thereby, the cloud of enclosure is gathering all over these 
research structures: biological samples are economic assets, subject 
to the bundle of property rights; genetic sequence derived from the 
sample could be patented or covered by a trade secret39; biobanks’ 
database can be protected by copyright or EU sui generis right40; 
also some contents of the databases are covered by copyright; the 
handling of personal data, health records and genetic information 
must preserve the donor’s right to privacy.  
Taking into account this panorama, we can distinguish two different 
levels in the biobank structure, based on the twofold nature of 
human biological samples. Biobanks, in fact, store a critical mass of 
tissues (leftover tissues, blood, saliva, urine, etc.) in their bio-
                                                          
39 The galaxy of intellectual property rights can be configured in a biobank has 
been described by Dove and Joly, 2012. 
40 The applicability of the sui generis right to research biobank has been tested in 
Ducato, 2013. In general, on the EU IPRs regime in the sector of the research 
data, see Dietr, Guibault, Margoni, Siewicz, Spindler and Wiebe 2013. 
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repositories; but however numerous they may be, biological samples 
are still exhaustible resources. They are scarce and rival assets that 
need to be efficiently allocated among stakeholders. On the 
contrary, data are “ubiquitous”: they can be replicated ‘n’ times and 
distributed to ‘n’ researchers at the same time. So, access to 
biological samples is crucial but access to the information derived 
from the material support is even more critical to the improvement 
of collaborative projects. In this paper we will focus only on this 
second dimension. 
Regulatory gaps and the lack of common and shared reference 
points have been filled by privatization trends, at the expense of the 
collective good and, in an increasing number of cases, at the 
expense also of private companies. In particular, traditional models 
seem to stifle a lot of potential for the biobank activities. For 
example, the tools ordinarily used for fruition of data and materials, 
the Material Transfer Agreement (MTA), are cause of unrest among 
researchers, because of the cumbersome nature of the mechanism, 
the length of the procedures and the high transaction costs41. 
Against this impasse some authors are invoking (and business 
models are moving towards) the ‘open’ movement42. 
 
                                                          
41 Streitz and Bennett, 2003; Ku, 2007; Rodriguez, 2008; Lei et al., 2009; Noonan, 
2009. Specifically on the problems related to MTA and possible solutions offered 
by Science Commons, see Margoni, 2013. 
42 Hess and Ostrom, 2007; Hope, 2008; Edwards et al. 2009, Weigelt, 2009, Lei at 
al., 2009; De Robbio and Corradi, 2010. For a precise description of the "open 
business models" see Chesbrough, 2006. 
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4. "Open Science": framing a slippery concept 
 
The vision that closed model systems, and patents in particular, 
encourage an efficient management of research, balancing the 
return on investments and the benefits for the whole community, 
has been strongly challenged in recent years43. This change is 
evidenced not only by the signal given by some ‘rebel’ researchers 
(e.g. Ilaria Capua)44, but even by big pharmaceutical companies (e.g. 
Novartis and Glaxo-SmithKline)45. BigScience becomes ‘open’ 
certainly not because of altruism: simply, they realized that 
cooperation is more convenient than competition based on IPRs. 
Despite the "openness" is a trend that is spreading in several areas, 
the core of the concept is vague and it is currently used for 
describing a varied landscape. As Maurer affirmed: "Open science is 
variously defined, but tends to connote (a) full, frank, and timely 
publication of results, (b) absence of intellectual property 
restrictions, and (c) radically increased pre- and post-publication 
                                                          
43 Kitch, 1977. With regard to the meaning of "openess" see Fecher and Friesike, 
2013; Destro Bisol et al., 2014.  
44 The Italian virologist identified the genetic sequence of the avian flu virus and 
decided to make it available to the worldwide scientific community by uploading 
it to GenBank, disregarding the invitation of the WHO to file it in a limited-
access database. See Enserink, 2006. 
45 Strauss, 2010. 
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transparency of data, activities, and  deliberations within research 
groups"46. 
What is certain is that the concept did not originate in the legal field, 
but it has been internalized in the legal thought as a result of a 
movement coming from two different technologies.  
Then, to understand what it means "open science" and how is 
spreading to the realm of biotechnology47, we have to contextualize 
the original concept of ‘open source’ in the world of software and 
the notion of "open access" in the context of scientific publications. 
Afterwards, we will discuss whether such concepts work if applied 
to scientific research in the ‘bio-’ fields48. 
 
 
4.1. Open Source and Open Access 
 
Open Source is a revolutionary and provocative concept, developed 
since the early '70s as part of computer science, and it represents a 
new way of thinking about computer programming and software in 
its entirety: from conception to final release and distribution. This 
movement is composed of two different souls: Free Software and 
Open Source Software. The first is linked to the name of Richard 
                                                          
46 Maurer, 2003. 
47 Delfanti, 2013. 
48 The following classifications were presented by Prof. Richard Gold during the 
seminar “Models for Sharing Data” within the Biobank Lab, held at the 
University of Trento in May 2010. 
 17 
 
Stallman49 and has an ethical aim. According to free software 
philosophy, proprietary software is a social problem that shakes the 
values of communality and sharing to its foundations. Software 
must be freely available and accessible without restraints as a 
desirable social outcome. On the contrary, Open Source Software is 
a definition created in 1998 on the occasion of the release of the 
source code of Netscape’s browser by Eric Raymond. According to 
these alternative currents, open source is a more efficient choice if 
compared to the traditional closed model50. The collaboration of 
different programmers, who at the same time are users, and the 
decentralized production monitored by strong expectations and 
sanctions are a synonym of quality, and they also reduce the costs 
and the time for the product development. 
Unless the starting point is different (the former school has a more 
philosophical and political approach, whereas the latter has a more 
utilitarian vision), the pragmatic result is the same. In fact, according 
to both Free Software and Open Source Software, in addition to the 
object-code (the machine-readable format) the source code is also 
distributed (the ‘human language’) to the public of user-
                                                          
49 In 1983 he announced the GNU project, an operative system compatible with 
Unix, the proprietary software more widespread in research laboratories in 
American universities. Stallman’s novel idea consisted in the creation of a license 
(copyleft, “all rights reversed”) giving much more power to the user than to the 
owner. About the origins of free software, see Stallman, 2002. 50 Raymond, 2000. 
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programmers51. In this way they can both use the software, and 
copy, modify and redistribute it52. According to the General Public 
License manifesto, free software gives users the four "fundamental 
freedoms": 0) run the program, for any purpose; 1) study how the 
program works, and change it to make it do what you wish; 2) 
redistribute copies; 3) distribute copies of your modified versions to 
others.  
Both ‘open projects’ are distinguished by a special legal regime that 
allows progressive developments. The GNU GPL, in fact, is a viral 
license because it “infects” all subsequent products containing the 
original code: the programmer gives up IP exploitation to follow-on 
users as the latter are not allowed to distribute the modified 
software with a proprietary license.  
It is hardly necessary to point out that this movement is not the 
negation of intellectual property, but rather represents a new way of 
interpreting it. It would be a mistake to think that copyleft means 
the absence of copyright. Viral licensing is properly designed under 
copyright law, but it allows users to modularize the availability and 
distribution of their works, while also posing some limits and 
obligations. 
                                                          
51 A way to overcome this problem is a particular technique called reverse 
engineering, where the reverser analyzes the programs and tries to understand 
how they work without having the source code. See Lessig, 1999; Nichols and 
Twidale, 2003. 
52 Stallman, 2004. 
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A concept that is often confused with the Open Source movement, 
but we have to keep conceptually distinct, is that of “Open Access 
(OA)”. Such an acronym indicates a literature that is “digital, online, 
free of charge, and free of most copyright and licensing 
restrictions”53. In the OA context two different routes have been 
distinguished, regularly labeled as “gold road” and “green road”54. 
The first one refers to OA journals; the second one to self-archiving 
previous published works.  
In a nutshell, the core of OA works as follows: the institution shall 
pay the cost of the publication of its researcher, who retains some 
rights (authorship, in particular) and surrenders others - throughout 
licenses such as Creative Commons55 – in order to make the 
publication freely available56. Here, production costs are borne by 
the authors and institutions, while distribution costs – held down 
thanks to digitization - are shared with new intermediaries.  
At the end, OA reduces costs, circumvents the limits imposed by 
increasingly stringent regulations on copyright, licensing agreements 
and Digital Rights Management (DRM). OA offers also reputational 
incentives, because it represents a means to disseminate authors’ 
                                                          
53 Suber, 2012; see also Willinsky, 2006; for an update literature review on the 
Open Access see Frosio, 2014. 
54 Harnad, Brody, Vallieres, Carr, Hitchcock, Gingras, Oppenheim, Stamerjoanns 
and Hilf, 2004; Guédon, 2004. 
55 Creative Commons (CC) is a charitable corporation that promotes the sharing 
and circulation of knowledge in compliance with copyright law. Although it offers 
standardized models, its modular licenses (attribution, noncommercial, no 
derivative works, share alike) and their combinations can provide flexibility in 
setting the interests of parties. Source: http://creativecommons.org/. 
56 Caso, 2009. 
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ideas, to spread their intellectual production, to promote themselves 
before other peers; but it is also a tool to get free and quick access 
to the literature necessary for implementing and deepening their 
own scientific production. OA is also an opportunity for libraries to 
mitigate the costs of journals and subscriptions57. Also, society and 
the progress of knowledge, in general, can benefit from such a 
system because the openness is the primary method for correcting 
errors and mistakes through the sociological mechanisms of peer 
review and citation58. 
However, authors play the key role in building a system based on 
open access, as the fate (open or closed) of their works is in their 
hands. It is a cultural problem (in the sense that part of scientific 
community still ignores what OA is) but is also a challenge to 
remove the existing disincentives (such as the Ingelfinger rule) and 
to find those incentives that could propitiate this mentality59. 
 
 
5. "Biotechnology Unchained": the tool of the "open patent" 
 
In the field of biomedical research and drug discovery, the open 
source philosophy has been transposed into “open source 
biotechnology”60. Of course such a transplant is not a trivial 
                                                          
57 De Robbio, 2010. 
58 Boyle, 1997. 
59 Suber, 2004a. 
60 Feldman and Nelson, 2008; Gitter, 2013. 
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question because the Open Source model and Open Source 
licensing have been developed around the idea and the structure of 
copyright. Instead, in what have been called open biotechnology, we 
have to deal with patents.  
At first sight, open source patent may seem a tautological expression, 
because the information related to the invention is already publicly 
accessible and available through the mechanisms of disclosure or 
deposit61. It implies that, even though the invention is disclosed, the 
information and data embodied are excludable. Patent itself may 
inhibit the public use of that invention through exclusive licenses. 
In this context, ‘open source’ refers to an issue of accessibility rather 
than disclosure62. 
Taking ideals behind the Free Software movement, the Open 
Source patenting develops “the aspirational goal of biological 
scientists [to] closely track those of the open source community in 
desiring to keep information and discoveries communal and 
accessible”63. Here, the ‘viral’ license works in the following terms: 
the licensees cannot appropriate the fundamental ‘kernel’ of the 
technology and any development must be shared at the same terms 
of the original technology64; data and results of research should fall 
into the public domain, but under certain requirements, for 
                                                          
61 Dasgupta and David, 1987. 
62 Boettinger and Burk, 2004. 
63 Ibid., p. 225. 
64 See BIOS concordance. Also Feldman, 2004; Feldman and Nelson, 2008; 
Torrance, 2009. 
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example, by waiving an "unfair" use of IPRs. The participants in the 
Open Source project, therefore, would agree to grant licenses or to 
exercise their rights in order to make inventions and improvements 
available to the whole community65. In this scenario, the patent 
holder should license the invention with a license that protects 
those technical solutions and improvements from possible attempts 
of appropriation, for example by commercial competitors. 
The main example of this philosophy is BIOS's CAMBIA, an 
Australian nonprofit research institute that has extended this model 
to the transfer of biological samples66. Users of the BIOS 
'concordance' do not assert IP rights against each other’s use of the 
technology, materials and methods to do research, or to develop 
products either for profit or for the public good. Consequently, the 
improvements must be shared according to a BIOS license, while 
the products and inventions developed from the same technology 
can be patented. In the latter case, however, the improvements that 
have been patented must return (grant back clause) to the BIOS and 
to other licensees on the same terms of the original license or must 
be freely cross-licensed. 
Some scholars have emphasized the advantages of this approach67. 
In fact, the absence of IP incomes is counterbalanced by a social 
                                                          
65 About the adoption of the open source model in the biotech field, Hope, 2008. 
66 BiOS stands for "Biological Innovation for Open Society) 
http://www.bios.net/daisy/bios/home.html  
67 In particular, it is possible to see the echo of the open source approach in the 
theorization of Parchomovsky and Mattioli, 2011. The authors propose two new 
types of patents - the "quasi patent" and the "semi-patent" - specifically thought 
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recognition for the participants68. This can also means economic 
rewards in terms of future job offers, proposals for collaboration in 
commercial open source companies and access to venture capital 
market69. 
However, the adoption of this system does not dissolve some key 
issues and the translation of the open source model outside the field 
of information technology raises a series of challenges70. First of all, 
there is a huge difference in the investments for R&D between the 
informatics and the biotech context71. Biotechnological research 
implies exorbitant costs for drug discovery processes, clinical trials, 
intellectual property management72. This factor can influence the 
social norms and the scientific behaviors toward the discovery 
process: the programmer could be more proactive in sharing his 
information while the researcher could adopt a more defensive 
approach towards his precious set of data73.  
The economic cost is not the only factor able to differentiate the 
two fields: the time is another key issue. Unlike what happens in 
programming, in biomedical research the process from discovery to 
marketing can take years or may not ever arrive at a marketable 
result. 
                                                                                                                               
for the biobanks sector. According to them, both patents would be compatible 
with the USPTO system and would mitigate the problem of patents related costs. 
68 von Hippel and von Krogh, 2003. 
69 Chakravarty, Haruvy and Wu, 2007; Hope, 2008. 
70 As pointed out by Boettinger and Burke, 2004. 
71 Lerner and Tirole, 2005; Torrance, 2009. 
72 de Beer, 2005. 
73 Gitter, 2013; Nicol, Caruso, and Archambault, 2013. 
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Therefore, the transplant of the Open Source philosophy in 
biotechnology would run a high risk of rejection. Open Source is a 
culture of sharing developed in the hacker community with 
different needs from the biotech world. Open Source, therefore, 
may not provide the right incentives for effective collaborative 
research74.  
 
 
6. Legal tools for opening the doors of biobanks 
 
Research biobanks have been metaphorically described as a library. 
This comparison is not so abstract since biobanks have both 
physical databases and digital archives.  
Digital databases of the biobanks may contain a variety of 
information. First of all, information related to the 'owner' of the 
sample like personal and clinical data, and additional information 
such as eating, life or relationship habits. Biobanks' databases can 
also index information derived from the material support, i.e. 
genetic data or sensitive information that can reveal the health 
conditions of the patient. In particular, genetic data are a very 
peculiar category because they concern not only the person they 
belong to but also his entire biological family. Quite often biobanks 
proceed to aggregate the data and to make the first analysis. 
Therefore the results of these analyses and the generated cohorts 
                                                          
74 As affirmed by Gold, 2013. 
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are included in digital files and stored in the archive for following 
research. We have also to consider that many biobanks are now 
linking their databases to the electronic health records of patients, 
thus creating a resource that contains a huge amount of data, 
constantly updated, reliable, and collected from healthcare 
professionals75. 
Moreover, since the main purpose of a biobank is to provide 
samples and data to researchers, while one of the main bonds of the 
latter is the reporting of his activities and the grant back of analysis' 
results, biobanks also collect the research reports and, if available, 
the publication derived from the study of the biological and 
informational resources provided. 
Within the digital archives of the biobank can therefore be 
stored copyrighted materials, and simple data. Regarding 
researchers’ reports and publication, the new methods offered by 
the Open Access in the field of scientific and academic commons 
(OpenWetWare76, PLoS77, Open Archive Initiative78, etc.) represent 
a great chance to transform research biobanks into an invaluable 
resource and a reference point. 
Concerning the diffusion of raw data, things may be a little bit 
different79. Since 2012, the Open Knowledge Foundation is carrying 
                                                          
75 Guarda, 2013. 
76 http://www.openwetware.org/. 
77 http://www.plos.org/. 
78 http://www.openarchives.org/. 
79 See, e.g., Reichman, Uhlir, 2003; Borgman, 2007, p. 115; The Royal Society 
Science Policy Centre, 2012. 
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out a project on "Open Data"80. The latter is the last application of 
the logic of "openness" in relation to data and content, and it can be 
summarized in the following terms: "Open data is data that can be 
freely used, re-used and redistributed by anyone - subject only, at 
most, to the requirement to attribute and share-alike"81. Moving 
from the awareness of the need of data's interoperability, the project 
provides a variety of waivers and licenses specifically suited for 
data82. One specific pilot is dedicated to the openness in science and 
research, where the working group encourages the sharing of 
publicly-funded research data (such as the results of medical trials, 
successful or otherwise) placing them in the Public Domain via 
PDDL or CC083. 
 
 
7. Open models and collaborative projects in the field of the life sciences 
 
Unless Open Data initiatives offers a valid legal tool, but they 
does not offer per se incentives to ensure their using by a single 
researcher84. They are likely to be abandoned if appropriate 
                                                          
80 This initiative has thus passed the open access protocols that were previously 
developed by Science Commons, which has now been re-integrated with Creative 
Commons http://sciencecommons.org/projects/publishing/open-access-data-
protocol/. 
81 See http://opendefinition.org/. 
82 For a complete overview: http://opendefinition.org/licenses/#Data. 
83 See the "Panton Principles" for ensuring open data in science: 
http://pantonprinciples.org/. 
84 On the incentives moving researchers see Borgman, 2007. 
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structures of governance are not established in order to allow their 
sustainability. It is necessary to involve all stakeholders in the design 
and management of these innovative projects, facilitating dialogue, 
participation and transparency85. 
In response to this gap, new paradigms are emerging for access 
to pre-competitive information, such as collaborative partnerships. 
Many new cases of private-public collaboration are demonstrating 
their value and biobanks may claim their IP power on them. 
One of the first example in this sense is represented by the 
‘HapMap Project’86, an international consortium involving ten 
research centres located in Japan, the UK, Canada, Nigeria, China 
and the USA. Its scope was to create a map of genetic variations in 
human beings - in order to offer a valid instrument in support of 
biomedical and clinical research - and make this information freely 
available. According to the Data Release Policies, in fact, all data 
generated must be released “quickly”87 in the public domain. The 
user accepts the terms of this agreement through a “click-wrap” 
license. In this way, the database is freely accessible to all bona fide 
researchers and users cannot tie down data and information by 
                                                          
85 Kranich, 2006. 
86 Internation HapMap Project, http://hapmap.ncbi.nlm.nih.gov/. See also 
Aa.Vv., 2003. 
87 See http://hapmap.ncbi.nlm.nih.gov/datareleasepolicy.html. It is not well 
specified how quick the release into the public domain has to be. 
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filing ‘patent parasite’88 application over the resulting discoveries. 
Researchers are forced to share information among the participants 
in the HapMap project, so bound by the same contractual 
provisions. In any case, the possibility of patenting is not excluded a 
priori: if it is possible to show a specific utility, researchers can apply 
for a patent “as long as this action does not prevent others from 
obtaining access to data from the Project”89, licensing the invention 
so that the information used is still accessible to other participants. 
More recently, other articulated solutions have emerged, such as the 
Structural Genomic Consortium (SGC)90, Sage Bionetworks91, the 
European Bioinformatics Institute (EBI) Industry Programme92, the 
Predictive Safety Testing Consortium (PSTC)93, the International 
Union of Basic and Clinical Pharmacology (IUPHAR)94, Life 
                                                          
88 According to Daniel de Beer a ‘patent parasite’ is a patent developed from the 
original material “to which just a tiny change has been made”. De Beer, 2005, p. 
366. 
89 HapMap Project, Data Release Policies. 
90 http://www.thesgc.org/. SGC is a non-profit organization founded in 2004 
with the aim of promoting the development of new drugs, investing in basic 
research and releasing to the public every type of information (from reagents to 
know-how) The SGC's primary goal is to determine the three-dimensional 
structure of proteins, in order to understand the molecular mechanisms of their 
biological function. Then, the data obtained are deposited in the Protein Data 
Bank (PDB), a freely accessible archive, which since 1971 collects information 
about 3D structures of large molecules, including proteins and nucleic acids 
(http://www.pdb.org/pdb/home/home.do). 
91 http://sagebase.org/. 
92 http://www.ebi.ac.uk/. 
93 http://c-path.org/pstc.cfm. 
94 http://www.iuphar.org/. 
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Science Grid – Eli Lilly, Pistoia95 and Innovative Medicines 
Initiative (IMI)96.  
These new business models are developing the idea of open 
innovation in the area of biomedical research97. That was expressly 
declared by Weigelt and Edwards when they launched SGC, an 
innovative project to foster the free circulation of pre-competitive 
data, based on the osmosis between private and public sector and 
the adoption of open access structures98. According to SGC Data 
Policies, all products and results (material and know-how) are 
released into the public domain, but the enforcement of this system 
is secured by a participatory and transparent governance structure, a 
number of clear operational rules and legal instruments, such as the 
adoption of CC licenses for the exchange of pre-competitive 
information99. 
Sage Bionetworks is another example in this sense. It is a not for 
profit organization founded in Seattle in 2009 with an ambitious 
goal: to create a "digital Commons" where computational biologists 
can improve an integrative bionetwork in order to expedite the 
pathway to knowledge, treatment, and prevention of disease (1st 
Sage Bionetworks Commons principle). The purpose is to build an 
innovation space where scientists are not limited to aseptically 
                                                          
95 http://www.pistoiaalliance.org/.  
96 http://www.imi.europa.eu/. 
97 Chesbrough, 2003. 
98 Edwards at al., 2009; Weigelt, 2009. 
99 Edwards at al., 2009. 
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exchange data, but, as active participants, they are calling to create 
new tools (models disease) or improve those developed by other 
colleagues100. So through an open IT infrastructure (the Sage 
Bionetworks Platform), standard tool-sharing mechanisms, secure 
measures and a cloud computing system, this model aims to 
become a powerful resource for data sharing and interoperability of 
different data sets. From the legal point of view, such goal has been 
pushed through the application of the CC Attribution Unported 
License for creative works and the CCO for data. 
On another side, this context is emblematic because highlights a 
latent tension: the values of open data are potentially in conflict 
with those of privacy. Information that is used in this kind of 
projects can also lie in personal data. 
In this sense, Sage Bionetworks has developed, based on the idea of 
Lunshof at al.101, a model of "Portable Legal Consent" (PLC), that is 
a "standardized informed consent system for anyone who has 
obtained data relevant to their health and would like to donate that 
data for research purposes"102. Data collected under these terms, if 
correctly de-identified, can be used and reuse without additional 
permission by all researchers who agrees both to protect the 
research participants and permit the public access to their results. 
The peculiar feature of this experimental bioethics protocol is the 
                                                          
100 Derry et al., 2012. 
101 Lunshof, Chadwick,Vorhaus, Church, 2008. 
102  http://sagecongress.org/WP/wp-
content/uploads/2012/04/PortableLegalConsentOverview.pdf 
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conscious involvement of patients: they are fully advised that the 
de-identification is not a complete and irreversible anonymisation; 
the development of the technology and the techniques of data 
aggregation can make intelligible what was not in accordance with 
the highest standards of protection adopted until some time ago. In 
this perpetual chase, Sage Bionetworks cannot assured a full 
protection against the loss of confidentiality. The patient who wants 
to participate must therefore be aware of the possible risks, 
predictable and not, that the online sharing of their DNA may 
result. 
Probably Sage Bionetworks is one the model which better 
interprets the democratization of innovation imagined by von 
Hippel, although we must admit that some of its solutions could 
create some frictions if applied in Europe, especially if we consider 
the implications of PLC for data protection law103. 
 
 
8. Concluding remarks: making the case for biobanks 
 
The English word “biobank” has in itself a theme connected to 
the world of finance (bank). In Italian we use the term "bioteca" 
which clearly has a resonance with the word “biblioteca” (library). It 
is a terminological choice suggesting a paradigm shift. The 
enclosure movement is dramatically expanding its borders to crucial 
                                                          
103 von Hippel, 2005. 
  32
sectors of innovation such as the pre-competitive area and is trying 
to colonize strategic structures like research biobanks. In this sense, 
the latter, like real banks, risk being transformed into a caveau104. 
Scholars have warned against this dangerous drift, underling the 
institutional and public role of biobanks: the latter is the steward of 
a critical mass of material and information, fundamental for 
biomedicine and translation medicine, which have to be used in a 
far-seeing and efficient way105.  
How to build this knowledge commons of the 21st Century? 
First of all, lawyers and policy makers should consider how the 
components of IP, technology, social norm and contracts interact in 
the specific context of research biobanks. As we have already 
emphasized, the biobank has a dual nature: a material and 
informational one. Therefore, the exchange of biological materials 
will be managed through an MTA, while for the data appropriate 
access policies must be created106. 
                                                          
104 De Robbio, 2010. 
105 According to the idea for the creation of knowledge commons through 
institutions and collective actions as outlined in Hess, Ostrom, 2007. See also 
Madison, Frischmann and Strandburg, 2010. 
106 The contractual component is the ideal solution in order to settle the parties' 
interests, but in the biobank context MTA is more the problem than the cure. 
Collaborative initiatives such as Science Commons have offered contractual 
models to make the transfer of research materials easier, thanks to a flexible, 
modular, web-based and user-friendly tool. However, this MTA has the usual 
disadvantages of standard agreement and its modularity partially alleviates the 
problem by providing a limited space for autonomy. On the one hand, 
standardization helps to reduce transaction costs and to facilitate circulation, but 
on the other hand, it creates difficulties in the field of open licences. Furthermore, 
a standard contract is always deficient in participatory aspects, because the 
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Why should researchers share information with others?107 
Although the benefits of data sharing are universally recognized108, 
the development of this process still faces technical and, above all, 
cultural problems109. At the same time, the abolition of the system 
of IPRs could not constitute an efficient response110. In order to 
elaborate possible solutions, firstly we must play on reputation and 
authorship, the unmoved mover of the openness of information. 
Scientific data sharing must be encouraged by creating appropriate 
reputational incentives, like a sort of h-index. The more you share 
with biobanks and the scientific community, the more you are cited 
and the more are the benefits. A researcher with a higher h-index 
could have priority access to material resources (biological samples) 
over other colleagues. Of course, access to immaterial resources of 
the biobanks should be granted for any research purposes, as 
broadly as possible, to all bona fide scientists, just after an online 
registration.  
The same ‘feedback’ incentive could be a valid tool also for the 
biobank itself and can address its funding problems. In the context 
                                                                                                                               
contents of the agreement do not result from a negotiation, but it is unilaterally 
imposed. On the problems related to the standardization of contracts, see Roppo, 
1975; Boggiano, 1991; Alpa and Bessone, 1997. 
107 See Borgman, 2007. 
108 Hess and Ostrom, 2003; Collins, 2010; Brooksbank, Todd Bergman, Apweiler, 
Birney and Thornton, 2014; Choudhury, Fishman, McGowan and Juengst, 2014 
(with regard to the importance of the sharing of data collection in neuroscience). 
109 An interesting analysis is presented by Andreoli Versbach and Mueller-Langer, 
2013. 
110 Merges, 2004. 
  34
of EU projects111, Anne Cambon-Thomsen has proposed the 
creation of a BRIF (Bioresource Research Impact Factor), a special 
citation impact factor in the case of biobanks112. Such a metrics 
should "trace the quantitative use of a bioresource, the kind of 
research using it and the efforts of the people and institutions that 
construct it and make it available", giving credit to those who 
created and maintained a valid resource.  
In order to spread data sharing, some authors have also proposed 
the adoption of a "grant back" clause: the researcher who uses a 
biobank should submit periodical reports as well as the results 
obtained113. However, this solution might turn into a disincentive 
because ethically controversial (it would force the self-determination 
of a researcher) and potentially inefficient (if a researcher is forced 
to share a result he may choose to use another resource that does 
not impose such a condition). In this sense, the US National 
Institutes of Health (NIH) have developed a temperament of the 
grant back clause: the investigator, who is performing genome-wide 
association studies with NIH fundings, must insert his data set into 
the NIH database of Genotypes and Phenotypes, but at the same 
time the NIH guarantee the exclusive right to publish the analysis 
and the results obtained by the dataset during a period of six 
                                                          
111 http://www.gen2phen.org/groups/brif-bio-resource-impact-factor. 
112 Cambon-Thomsen, Thorisson and Mabile, 2011. Ut represents the evolution 
of the BIF, Biobank impact factor proposed bu Cambon-Thomsen, 2003. See 
also, De Castro, Calzolari, Napolitani, Rossi, Mabile, Cambon-Thomsen and 
Bravo, 2013. 
113 As already mentioned about the "HapMap Project". 
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months114. This balancing solution is based on the assumption that 
data derived from GWAS studies are pre-competitive and, 
therefore, a strong provision favouring its "enclosure" would block 
patents, downstream discoveries and future research115. 
These recent trends towards openness show fascinating 
perspectives but may paradoxically become a closure unless we 
learn to handle all these new possibilities. Lawyers must return to 
being the finest interpreters of contract law, in order to modulate a 
system of incentives that take into account the following steps: 
defining the organization (public, private or partnership); 
establishing the governance structure and transparent data access 
policies; engaging patients and research participants; elaborating 
types of contracts and licences, considering the dual nature of the 
biobank and consequently the different object (digital information 
or biological material). The complexity lies in the management of 
the interface between copyright and patent. It represents the main 
challenge of this contractual drafting where lawyers still have 
something to say. 
  
                                                          
114 The NIH Genomic Data Sharing Policy has been recently updated (August 28, 
2014). See the new version here: http://gds.nih.gov/03policy2.html. Before such 
a modification, the period of exclusivity was up to twelve months. 
115 http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-088.html. 
  36
Bibliography 
 
Aa Vv (2003) The International HapMap Consortium. Nature 
426:789-796 
Alpa G, Bessone M (1997) Il contratto standard nel diritto interno e 
comunitario. Torino, Giappichelli 
Andreoli Versbach P, Mueller-Langer F (2013) Open access to data: 
an ideal professed but not practised. RatSWD Working Paper Series 
No. 215; Max Planck Institute for Intellectual Property & 
Competition Law Research Paper No. 13-07. Available at SSRN: 
http://ssrn.com/abstract=2224146 or 
http://dx.doi.org/10.2139/ssrn.2224146  
Annas G J (1988) Whose waste is it anyway? The case of John 
Moore. The Hastings Center Report 18:37-39 
Boettinger S, Burk D L (2004) Open source patenting. J. Int'l 
Biotechnol. L. 1:221-231 
Boggiano A (1991) International standard contracts: the price of 
fairness. Grham & Trotman, Dordrecht 
Booth B, Zemmel R (2004) Prospects for productivity. Nat. Rev. 
Drug Discov. 3:451-457 
Borgman C L (2007) Scholarship in the digital age: information, 
infrastructure and the Internet. MIT Press 
Boyle J (2008) The public domain: enclosing the commons of the 
mind. Yale University Press 
 37 
 
Boyle J (2003) The second enclosure movement and the 
construction of the public domain. Law & Contemp. Probs. 66:33-
74 
Boyle J (1997) Shamans, software and spleens: law and construction 
of the information society. Harvard, Harvard University Press 
Brooksbank C, Todd Bergman M, Apweiler R, Birney E, Thornton 
J (2014) The European Bioinformatics Institute’s data resources 
2014. Nucleic Acids Research, 42:D18-D25 
Burrow B (1997) Second thoughts about U.S. Patent #4,438,032, 
Bull. Med. Ethics 124:11-14 
Cambon-Thomsen A (2003) Assessing the impact of biobanks. 
Nature Genet. 34:25–26 
Campbell E P (2006) Patent rights in biological material. 
Biobusiness Legal Affairs. Available at: 
http://www.genengnews.com/articles/chitem.aspx?aid=1880 
Caso R, Ducato R (2013) Opening research biobanks: an overview. 
In: Pascuzzi G, Izzo U, Macilotti M (eds) Comparative issues in the 
governance of research biobanks. Heidelberg, Springer, pp. 209-229 
Caso R (2009) L’open access alle pubblicazioni scientifiche: una 
nuova speranza. In: Caso R. (ed), Pubblicazioni scientifiche, diritto 
d'autore e open access, Trento, Università degli Studi di Trento, pp 
7-45. Available at: http://eprints.biblio.unitn.it/1589/ 
Caso R (ed.) (2005) Ricerca scientifica pubblica, trasferimento 
tecnologico e proprietà intellettuale, Bologna, Il Mulino 
  38
Chakravarty S, Haruvy E, Wu F (2007) The link between incentives 
and product performance in open source development: an empirical 
investigation. Global Bus. & Econ. Rev. 9:151-169 
Chesbrough H (2006) Open business models: how to thrive in the 
new innovation landscape. Boston, Harvard Business School Press 
Choudhury S, Fishman J, McGowan M, Juengst E (2014) Big data, 
open science and the brain: lessons learned from genomics. Front. 
Hum. Neurosci. 239(8):1-10. Also available at 
http://journal.frontiersin.org/Journal/10.3389/fnhum.2014.00239/
full 
Collins F (2010) Has the Revolution Arrived?. Nature 464:674, 675 
Conley J M, Doerr A K, Vorhaus D B (2010) Enabling responsible 
public genomics. Health Matrix 20:325- 385 
Corian B, Weinstein O (2011) Patent regimes, firms and the 
commodification of knowledge. Socioecon. Rev. 10:1-26 
Cuatrecasas P (2006) Drug discovery in jeopardy. J. Clin. Invest. 
116:2837-2843 
Dasgupta P, David P (1987) Information disclosure and the 
economics of science and technology. In: Feiwel G (ed) Arrow and 
the ascent of modern economic theory. New York, New York 
University Press, pp 519-42 
De Beer  D (2005) Is Open-sourced biotechnology possible?. In: 
Marleen Wynants & Jan Cornelis  (eds), How open is the future? 
economic, social & cultural scenarios inspired by free & open-
 39 
 
source software, Brussels, VUB Brussels University Press, pp 357-
372 
De Castro P, Calzolari A, Napolitani F, Rossi A M, Mabile L, 
Cambon- Thomsen A, Bravo E (2013) Open data sharing in the 
context of bioresources, Acta Inform. Med. 21(4): 291-292 
Delfanti A (2013) Biohackers: the politics of open science, Pluto 
Press, London 
De Robbio A (2010) Biobanche e proprietà intellettuale: commons 
o caveau?. Available at: 
http://didattica.spbo.unibo.it/bibliotime/num-xiii-3/derobbio.htm 
De Robbio A, Corradi A (2010) Biobanche in bilico tra proprietà 
privata e beni comuni: brevetti o open data sharing?. JLIS.it. 1: 305–
329 
Derry J, Mangravite L, Suver C, Furia M, Henderson D, 
Schildwachter X, Izant J, Sieberts S, Kellen M, Friend S (2012) 
Developing predictive molecular maps of human disease through 
community-based modeling. Nature Genetics 44:127–130 
Destro Bisol G, Anagnostou P, Capocasa M, Bencivelli S, Cerroni 
A, Contreras J, Enke N, Fantini B, Greco P, Heeney C, Luzi D, 
Manghi P, Mascalzoni D, Molloy J C, Parenti F, Wicherts J M, 
Boulton G (2014) Perspectives on open science and scientific data 
sharing:an interdisciplinary workshop, Journal of Anthropological 
Sciences 92:179-200 
Dietr N, Guibault L, Margoni T, Siewicz K, Spindler G, Wiebe A 
(2013) Safe to be open: study on the protection of research data and 
  40
recommendations for access and usage. OpenAirePlus. Available at 
SSRN: http://ssrn.com/abstract=2391280 
Dove E S, Joly Y (2012) The contested futures of biobanks and 
intellectual property. Theory & Law. Teorder 11(1): 132-146 
Ducato R (2013) "Adiós Sui Géneris". A study of the legal feasibility 
of the sui generis right in the context of research biobanks. Law and 
the Human Genome Review, 38: 125-146. Also available 
at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2330488 
Edwards A M, Bountra C, Kerr D J, Willson T M (2009) Open 
access chemical and clinical probes to support drug discovery. 5 
Nat. Chem. Biol. 7:436 
Enserink M (2006) Italy's influenza diva. Science 314:918-919 
Fecher B, Friesike S (2013) Open science: one term, five schools of 
thought. RatSWD_WP_ 218. Available at SSRN: 
http://ssrn.com/abstract=2272036 or 
http://dx.doi.org/10.2139/ssrn.2272036  
Feldman R, Nelson K (2008) Open source, open access, and open 
transfer: market approaches to research bottlenecks, 7 Nw. J. Tech. 
& Intell. Prop. 14. Also available at 
http://ssrn.com/abstract=1127571 
Feldman R (2004) The Open source biotechnology movement: is it 
patent misuse?. Minn. J.L. Sci. & Tech. 6(1):117-167 
FitzGerald G A (2005) Anticipating change in drug development: 
the emerging era of translational medicine and therapeutics. Nat. 
Rev. Drug Discov. 4:815-818 
 41 
 
Frosio G B (2014) Open access publishing: a literature review, 
CREATe working paper 2014/1,. Available at: 
http://www.create.ac.uk/wpcontent/uploads/2014/01/CREATe-
Working-Paper-2014-01.pdf 
Gitter D M (2013) The challenges of achieving open source sharing 
of biobank data. In: Pascuzzi G, Izzo U, Macilotti M (eds) 
Comparative issues in the governance of research biobanks. 
Heidelberg, Springer, pp. 165-189 
Gold R E, Nicol D (2013) Beyond open source: patents, biobanks 
and sharing. In: Pascuzzi G, Izzo U, Macilotti M (eds) Comparative 
issues in the governance of research biobanks. Heidelberg, Springer, 
pp. 191- 208 
Gold R E (2010) Models for sharing data. Seminar at the 
Department of Law, University of Trento 
Guarda P (2013) Biobanks and electronic health records: open 
issues. In: Pascuzzi G, Izzo U, Macilotti M (eds) Comparative issues 
in the governance of research biobanks. Heidelberg, Springer, pp. 
131-141 
Grafton A, Eisenstein E, Johns A (2002) How revolutionary was 
the print revolution?. AHR 1:84-128 
Granieri M (2010) La gestione della proprietà intellettuale nella 
ricerca universitaria. Invenzioni accademiche e trasferimento 
tecnologico. Bologna, Il Mulino  
  42
Guédon J C (2004) The «green» and «gold» roads to Open Access: 
the case for mixing and matching. Available at: 
http://eprints.rclis.org/archive/00003039/01/science.pdf 
Hardin G  (1968) The tragedy of the commons. Science 162: 1243–
1248 
Harnad S, Brody T, Vallieres F, Carr L, Hitchcock S, Gingras Y, 
Oppenheim C, Stamerjoanns H, Hilf E R (2004) The green and the 
gold roads to Open Access, in Nature (web focus). Available at: 
http://www.nature.com/nature/focus/accessdebate/21.html 
Heller M A (1999). The boundaries of private property. Yale L. J. 
108:1163–1223 
Heller M A (1998). The tragedy of the anticommons: Property in 
the transition from Marx to markets. Harv. L. Rev. 111:621–688 
Heller M A, Eisenberg R S (1998) Can patents deter innovation? 
The anticommons in biomedical research. Science 280:698-701 
Hess C, Ostrom E (2007) Understanding knowledge as a commons. 
Cambridge, Mass., MIT University Press 
Hess C, Ostrom E (2003) Ideas, Artifacts, and Facilities: 
Information as a Common-Pool Resource. Law & Contemp. Probs. 
66: 111-145  
Hipkens H L (1992) Failed search for the perfect analogy: more 
reflections on the unusual case of John Moore. Ky. L. J. 80:337-352 
Hippel von E (2005) Democratizing innovation. Cambridge, Mass., 
MIT Press 
 43 
 
Hippel von E, Krogh von G (2003) Open source software and the 
‘private-collective’ innovation model: issues for organization 
science. Organization science14: 209-223 
Hope J (2008) Biobazaar: The open source revolution and 
biotechnology. Cambridge, Mass., Harvard University Press 
ICSU (2004) Report of the CSPR assessment panel on scientific 
data and information. http://www.science-softcon.de/cspr.pdf 
Javitt G (2010) Why not take all of me? Reflections on the immortal 
life of Henrietta Lacks and the status of participants in research 
using human specimens. Minn. J. L. Sci. & Tech. 11:713-754 
Kaye J (2012) The tension between data sharing and the protection 
of privacy in genomics research. Annu. Rev. Genomics Hum. 
Genet. 13:415–431 
Kesselheim A S, Cook-Deegan R M, Winickoff D E, Mello M M 
(2013) Gene Patenting—The Supreme Court Finally Speaks. N. 
Engl. J. Med. 369(9): 869-875 
Kinney A J, Krebbers E, Vollmer S J (2004) Publications from 
industry. Personal and corporate incentives. Plant. Physiology. 134: 
11–15 
Kitch E (1977) The nature and the function of the patent system. J. 
of Law and Econ. 20: 265-290 
Kranich N (2006) Countering enclosure: reclaiming the knowledge 
commons. In: Hess C, Ostrom E (eds) Understanding knowledge as 
a commons, Cambridge, Mass., MIT Press, pp 85-122 
  44
Ku K (2007) Point: MTAs are the bane of our existence!. Nat. 
Biotechnol. 25: 721-722  
Ladas S (1929) The efforts for international protection of scientific 
property. Am. J. Int'l L. 23: 555-559 
Landecker H (1999) Between beneficence and chattel: the human 
biological in law and science. Sci. Context 12: 203-225 
Landes W M, Posner R A (2003) The economic structure of 
intellectual property law. Cambridge, Mass., Harvard University 
Press 
Lei Z, Juneja R, Wright B D (2009) Patents versus patenting: 
implications of intellectual property protection for biological 
research. Nat. Biotechnol. 27:3 6-40 
Lei Z, Wright B D (2009) Reply to conflating MTAs and patents. 
Nat. Biotechnol. 27:505-506 
Lerner J, Tirole J (2005) The economics of technology sharing. 
Open source and beyond. J. Econ. Perspect. 19: 99-120 
Lessig L (2004) Free culture: the nature and future of creativity. 
New York, Penguin Books 
Lessig L (2004) How I lost the Big One. Available at: 
http://www.legalaffairs.org/issues/March-April-
2004/story_lessig_marapr04.msp 
Lessig L (1999) The limit in open code: regulatory standards and the 
future of the net. Berkley Tech. L. J. 14: 759-769 
 45 
 
Lucey B P, Nelson-Rees W A, Hutchins G M (2009) Henrietta 
Lacks, HeLa cells, and cell culture contamination. Arch. Pathol. 
Lab. Med. 133: 1463-1467 
Lunshof J, Chadwick R, Vorhaus D B, Church G M (2008) From 
genetic privacy to open consent. Nat. Rev. Gen. 9:406-411 
Macilotti M (2013) Le biobanche di ricerca. Studio comparato sulla 
«zona grigia» tra privacy e proprietà. Trento, Università degli Studi 
di Trento 
Madison M J, Frischmann B M, Strandburg J M (2010) 
Constructing commons in the cultural environment. Cornell Law 
Review, Vol. 95, 657, U. of Pittsburgh Legal Studies Research Paper 
No. 2008-26. Available at SSRN: 
http://ssrn.com/abstract=1265793 
Margoni T (2013) The roles of material transfer agreements in 
genetics databases and bio-banks. In: Pascuzzi G, Izzo U, Macilotti 
M (eds) Comparative issues in the governance of research biobanks. 
Heidelberg, Springer, pp 231-250 
Maurer S M (2003) New institutions for doing science: from 
databases to open source biology, online at: 
http://www.epip.eu/papers/20031124/200411_conference/papers
/maurer_paper.pdf 
Mazzoleni R, Nelson R R (1998) The benefits and costs of strong 
patent protection: a contribution to the current debate. Research 
Policy 27: 273-284 
  46
Menell P S (1999) Intellectual property: general theories. In: 
Bouckaert B, De Geest G, Encyclopedia of Law and Economics, 
Cheltenham, Edward Elgar, pp 129-188 
Merges R P (2011) Justifying intellectual property. Cambridge, 
Mass., Harvard University Press 
Merges R P (2004) A new dynamism in the public domain. U. Chi. 
L. Rev. 17(1):183-203 
Michelman F I (1967) Property, utility and fairness: comments on 
the ethical foundations of just compensation law. Harv. L. Rev. 80: 
1165–1258 
Mowery D C, Sampat B N (2005) The Bayh-Dole Act of 1980 and 
university industry technology transfer: a model for other OECD 
governments?. JTT 30: 115-127 
Mowery D C, Nelson R R, Sampat B N, Ziedonis A A (2004) Ivory 
tower and industrial innovation. University-industry technology 
transfer before and after the Bayh-Dole Act. Palo Alto, Standford 
University Press 
Mowery D C (1998) Collaborative R&D: how effective is it?. Issues 
in Science and Technology. Available at: 
http://www.issues.org/15.1/mowery.htm 
Murray F, Stern S (2007) Do formal intellectual property rights 
hinder the free flow of scientific knowledge? An empirical test of 
the anti-commons hypothesis. J. Econ. Behav. Organ. 63: 648–687 
Nelson R R (2001) Observations on the post-Bahy-Dole rise of 
patenting at American universities. JTT 26: 13-19 
 47 
 
Nichols D, Twidale M (2003) The usability of open source software. 
Available at: 
http://frodo.lib.uic.edu/ojsjournals/index.php/fm/article/view/10
18/939 
Nicol A, Caruso J, Archambault E (2013) Open data access policies 
and strategies in the European research area and beyond, European 
Commission and Science Metrix. Available at: http://www.science-
metrix.com/pdf/SM_EC_OA_Data.pdf 
Noonan K (2009) Conflating MTAs and patents. Nat. Biotechnol. 
27: 504-505  
Nordhaus W D (1969) Invention, growth and welfare: a theoretical 
treatment of technological change. Cambridge, Mass., MIT Press 
O’ Brien S J (2001) Cell culture forensics. PNAS 14: 7656-7658 
Paganelli M (1989) Alla volta di Frankestein: biotecnologie e 
proprietà (di parti) del corpo. Foro it IV: 417-441 
Parchomovsky G, Mattioli M (2011) Partial patents. Colum. L. Rev. 
111:207-253 
Parisi F, Schulz N, Depoorter B (2005), Duality in property: 
commons and anticommons. Int'l Rev. L. & Econ. 25: 578–591 
Perkmann M, West J (2014) Open science and open innovation: 
sourcing knowledge from universities. In: The Chicago handbook 
of university technology transfer and academic entrepreneurship. 
The University of Chicago Press. Forthcoming. Available at SSRN: 
http://ssrn.com/abstract=2133397 
  48
Plant A (1934) The economic aspects of copyright in books, 
Economica 1: 167-195  
Plant A (1934) The economic theory concerning Patents for 
Inventions. Economica 1: 30-51 
Rai A, Eisenberg R (2003) Bayh-Dole reform and the progress of 
biomedicine. Law and Contemporary Problems 66:289-314 
Raymond E S (2000) The cathedral and the bazaar. Available at: 
http://www.catb.org/~esr/writings/homesteading/cathedral-
bazaar/ 
Reichman J H, Okediji R (2012) When copyright law and science 
collide: empowering digitally integrated research methods on a 
global scale, in Minnesota Law Review, Vol. 96, No. 4; Minnesota 
Legal Studies Research Paper, pp 12-54. Available at SSRN: 
http://ssrn.com/abstract=2149218 
Reichman J H, Uhlir P F (2003) The public domain: a contractually 
reconstructed research commons for scientific data in a higly 
protectionist intellectual property environment. Law & Contemp. 
Prob. 66:315-462 
Resta G (2011) La privatizzazione della conoscenza e la promessa 
dei beni comuni: riflessioni sul caso "Myriad Genetics". Riv. critica 
dir. privato, 281 
Rodriguez V (2008) Governance of material transfer agreements, 
Technol. Soc. 30: 122-128  
Roppo E (1975) Contratti standard: autonomia e controlli nella 
disciplina delle attività negoziali di impresa. Milano, Giuffrè 
 49 
 
Samuelson P (2003) The constitutional law of intellectual property 
after Eldred v. Ashcroft. Available at:  
http://people.ischool.berkeley.edu/~pam/papers/post-Eldred.pdf 
Shapin S, Schaffer S (1985) Leviathan and the air-pump: Hobbes, 
Boyle, and the experimental life. Princeton, Princeton University 
Press 
Skloot R (2010) The immortal life of Henrietta Lacks. New York, 
Crown Publishers 
Solow R M (1957) Technical change and the aggregate production 
function. Rev. Econ. Stat. 39:312-320 
Stallman R (2002) Free software, free society. Available at: 
http://www.gnu.org/doc/fsfs-ii-2.pdf 
Strauss S (2010) Pharma embraces open source models. Nat. 
Biotechnol. 28:631-634  
Streitz W D, Bennett A B (2003) Material transfer agreements: a 
university perspective. Plant. Physiol. 133: 10–13 
Suber P (2012) Open Access, MIT Press, Cambridge (MA) 
Suber P (2004) Open Access overview: focusing on open access to 
peer-reviewed research articles and their preprints. Available at: 
http://www.earlham.edu/~peters/fos/overview.htm 
Summit R. (2002) Reflections on the beginnings of dialog: the birth 
of online information access. Available at: 
http://support.dialog.com/publications/chronolog/200206/jun200
2.pdf 
  50
The Royal Society Science Policy Centre (2012) Science as an open 
enterprise, Available at: 
https://royalsociety.org/~/media/policy/projects/sape/2012-06-
20-saoe.pdf 
Tomasson M (2009) Legal, ethical, and conceptual bottlenecks to 
the development of useful genomic tests. Ann. Health L. 18:231- 
260 
Torrance A W (2009) Open source human evolution. J.L. & Pol'y 
30:93- 138 
Van Overwalle G (2014) Governing genomic data: plea for an 
'Open Commons'. In: Madison M, Frischmann B, Strandburg K 
(eds) Governing the knowledge commons. Oxford University Press, 
pp 137-153. Available at SSRN: http://ssrn.com/abstract=2477897 
Weigelt J (2009) The case for open-access chemical biology. EMBO 
reports 10:941-945 
Willinsky J (2006) The access principle – The case for open access 
to research and scholarship. MIT Press, Cambridge (MA) 
Winickoff D E (2008) From benefit sharing to power sharing: 
partnership governance in population genomics research. Available 
at: http://escholarship.org/uc/item/845393hh.  
 
 
 
 
 51 
 
The Trento Lawtech Research Paper Series is 
published since Fall 2010  
1. Giovanni Pascuzzi, L’insegnamento del diritto comparato nelle 
università italiane (aggiornamento dati: dicembre 2009) - The 
Teaching of Comparative Law in Italian Universities (data updated: 
December 2009), Trento Law and Technology Research Group 
Research Papers, October 2010.  
2. Roberto Caso, Alle origini del copyright e del diritto d'autore: 
spunti in chiave di diritto e tecnologia - The Origins of Copyright 
and Droit d'Auteur: Some Insights in the Law and Technology 
Perspective, Trento Law and Technology Research Group Research 
Papers; November 2010.  
3. Umberto Izzo, Paolo Guarda, Sanità elettronica, tutela dei dati 
personali e digital divide generazionale: ruolo e criticità giuridica 
della delega alla gestione dei servizi di sanità elettronica da parte 
dell’interessato - E-health, Data Protection and Generational Digital 
Divide: Empowering the Interested Party with the Faculty of 
Nominating a Trusted Person Acting as a Proxy when Processing 
Personal Health Data within an Electronic PHR, Trento Law and 
Technology Research Group Research Papers; November 2010.  
4. Rossana Ducato, “Lost in Legislation”: il diritto multilivello 
delle biobanche di ricerca nel sistema delle fonti del diritto 
(convenzioni internazionali, leggi europee, nazionali e regionali, 
softlaw) - “Lost in legislation”: The Multilevel Governance of 
Research Biobanks and the Sources of Law (International 
Conventions, European, National and Regional legislations, 
Softlaw), Trento Law and Technology Research Group Research 
Papers; December 2010.  
  52
5. Giuseppe Bellantuono, The Regulatory Anticommons of Green 
Infrastructures, Trento Law and Technology Research Group 
Research Papers; February 2011.  
6. Francesco Planchenstainer, La regolamentazione dell’acqua 
destinata ad impiego alimentare: analisi storico comparativa dei 
differenti approcci sviluppati negli USA e nella UE - The Regulation 
Of Water For Nutritional Use: A Comparative and Historical 
Analysis of the Different Approaches Developed in US and EU 
Law, Trento Law and Technology Research Group Research 
Papers; April 2011. 
7. Roberto Caso, Giovanni Pascuzzi, Valutazione dei prodotti 
scientifici nell’area giuridica e ruolo delle tecnologie digitali – 
Evaluation of Scientific Products in the Legal Field and the Role of 
Digital Technologies, Trento Law and Technology Research Group 
Research Papers; May 2011. 
8. Paolo Guarda, L'Open Access per la dottrina giuridica e gli 
Open Archives: verso un futuro migliore? - Open Access to legal 
scholarship and Open Archives: toward a Better Future?, Trento 
Law and Technology Research Group Research Papers; November 
2011. 
9. Thomas Margoni, Eccezioni e limitazioni al diritto d'autore in 
Internet - Exceptions and Limitations to Copyright Law in the 
Internet, Trento Law and Technology Research Group Research 
Papers; January 2012. 
10. Roberto Caso, Plagio, diritto d’autore e rivoluzioni 
tecnologiche - Plagiarism, copyright and technological revolutions. 
Trento Law and Technology Research Group Research Papers; 
February 2012. 
 53 
 
11. Giovanni Pascuzzi, Diventare avvocati e riuscire ad esserlo: 
insegnare l’etica delle professioni forensi attraverso le trame 
narrative - How to become lawyers and able to do so: teaching the 
ethics of the legal profession through narrative, Trento Law and 
Technology Research Group. Research Papers; July 2012. 
12 Umberto Izzo, IL ‘Contratto sulla neve’ preso sul serio: due 
modelli di contratto (per la fruizione delle aree sciabili e per 
l'insegnamento sciistico) – Taking the ‘Contract on the Snow’ 
Seriously: Two Model Contracts (For Accessing and Using the Ski 
Area, and For the Teaching of Skiing), Trento Law and Technology 
Research Group Research Paper; 2012. 
13. Francesco Planchestainer, “They Collected What Was Left of 
the Scraps”: Food Surplus as an Opportunity and Its Legal 
Incentives, Trento Law and Technology Research Group Research 
Paper; Febraury 2013.  
14. Roberto Caso, I libri nella “tempesta perfetta”: dal copyright al 
controllo delle informazioni digitali - Books into the “perfect 
storm”: from copyright to the control of information, Trento Law 
and Technology Research Group Research Paper; March 2013. 
15. Andrea Rossato, Beni comuni digitali come fenomeno 
spontaneo - Digital Commons as a Spontaneous Phenomenon, 
Trento Law and Technology Research Group Research Paper; May 
2013. 
16. Roberto Caso, Scientific knowledge unchained: verso una 
policy dell’università italiana sull’Open Access - Scientific 
knowledge unchained: towards an Open Access policy for Italian 
universities, Trento Law and Technology Research Group Research 
Paper; May 2013 
  54
17. Valentina Moscon, Copyright, contratto e accesso alla 
conoscenza: un’analisi comparata - Copyright, contract and access 
to knowledge: a comparative analysis, Trento Law and Technology 
Research Group Research Paper; December 2013 
18. Roberto Caso, La via legislativa all’Open Access: prospettive 
comparate - The legislative road to Open Access: comparative 
perspectives, Trento Law and Technology Research Group 
Research Paper; January 2014 
19. Roberto Caso, Misure tecnologiche di protezione: cinquanta (e 
più) sfumature di grigio della Corte di giustizia europea, Trento Law 
and Technology Research Group Research Paper; March 2014 
20. Federica Giovanella, Enforcement del diritto d'autore 
nell'ambito di Internet vs. protezione dei dati personali: 
bilanciamento tra diritti fondamentali e contesto culturale, Trento 
Law and Technology Research Group Research Paper; April 2014 
21. Umberto Izzo, Rossana Ducato, The Privacy of Minors 
within Patient-Centered eHealth Systems, Trento Law and 
Technology Research Group Research Paper; June 2014 
